RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-23 08:45
Prospectus
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Regulatory News Service
確認書
Japanese 7.9 KB
2025-06-20 03:49
Regulatory News Service
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
Regulatory News Service
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Regulatory News Service
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Regulatory News Service
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Regulatory News Service
確認書
Japanese 7.9 KB
2023-11-13 08:01
Quarterly Report
四半期報告書-第21期第2四半期(2023/07/01-2023/09/30)
Japanese 203.1 KB
2023-08-10 08:46
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan 7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.